Display Settings:

Format

Send to:

Choose Destination
Eur Neuropsychopharmacol. 2008 Sep;18(9):623-7. doi: 10.1016/j.euroneuro.2008.06.003. Epub 2008 Jul 14.

A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants.

Author information

  • 1Medical Products Agency, P.O. Box 26, SE-751 03 Uppsala, Sweden. hans.melander@mpa.se

Abstract

Data on percentage of patients experiencing a relevant response (>50% reduction of the baseline Hamilton Depression Scale (HAMD) score), average baseline severity and sample size were retrieved for all placebo-controlled studies in regulatory submissions of SSRIs and SNRIs between 1984 and 2003. Overall there was 16%-units (95% CI: 12; 20) more responders on active drug compared to placebo. There was no evidence of a diminishing magnitude of effect with lower severity at baseline. With one exception significant differences varying between 13.5 and 19.3%-units were demonstrated for the individual antidepressants. Statistically significant mean differences versus placebo in change in HAMD are not a proper basis for evaluation of clinical relevance and are not sufficient for approval. Differences in the percentage of patients experiencing a clinically relevant response should also be demonstrated. In this respect, the approved SSRIs and SNRIs were found superior to placebo, independent of severity of depression.

PMID:
18621509
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk